Advertisement


Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease

2018 ASCO Annual Meeting

Advertisement

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss two treatment studies: one testing pegilodecakin with nivolumab or pembrolizumab and the other evaluating an oral CXCR4 inhibitor in combination with axitinib (Abstracts 4509 & 4510).



Related Videos

Breast Cancer

Andrew D. Seidman, MD, and Susan F. Dent, MD, on Breast Cancer: Analysis of the SANDPIPER Trial

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Susan F. Dent, MD, of The Ottawa Hospital Cancer Centre, analyze the phase III study findings...

Prostate Cancer

Susan Halabi, PhD, on Prostate Cancer: Overall Survival for Black vs White Men

Susan Halabi, PhD, of Duke University Medical Center, discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had me...

Breast Cancer
Immunotherapy

Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial

Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early b...

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Lauren C. Harshman, MD on RCC: Results From the PROSPER Trial

Toni K. Choueiri, MD, and Lauren C. Harshman, MD, both of Dana-Farber Cancer Institute, discuss phase III study findings on perioperative nivolumab vs observation ...

Lung Cancer
Immunotherapy

Gilberto Lopes, MD, MBA, on NSCLC: Results From the KEYNOTE-042 Trial

Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, discusses phase III findings on pembrolizumab vs platinum-based chemotherapy as fi...

Advertisement

Advertisement



;
Advertisement